Medicines Classification




NEW ZEALAND GAZETTE, No. 11

2 FEBRUARY 2012

Schedule 1

Prescription Medicines

5-aminolevulinic acid
Afamelanotide
Amorolfine; except when specified elsewhere in this notice; except in preparations for the treatment of tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
Apixaban
Asenapine
Belimumab
Boceprevir
Cyclizine; except when specified elsewhere in this notice
Clotrimazole; except in medicines for vaginal or external use
Dapagliflozin propanediol
Degarelix
Denosumab
Diclofenac; in preparations for the treatment of solar keratosis; except when specified elsewhere in this notice; except in preparations for external use other than for the treatment of solar keratosis
Dronedarone
Econazole; except in medicines for vaginal or dermal use
Eculizumab
Ferric carboxymaltose
Fingolimod
Guaiphenesin; for oral use in medicines containing more than 2% or 200 milligrams per dose form except when specified elsewhere in this notice; except for oral use in modified release form with a maximum recommended daily dose of not more than 2.4 grams when sold in the manufacturer’s original pack containing not more than 10 days’ supply
Icatibant
Indacaterol
Ipilimumab
Isoconazole; except in medicines for vaginal or dermal use
Linagliptin
Lovastatin; except when present as an unmodified, naturally occurring substance in a food that has not been subject to a manufacturing process other than heating, freezing, drying, preserving, bottling, canning, or packaging in retort pouches
Mercurochrome; except when specified elsewhere in this notice
Miconazole; except when specified elsewhere in this notice; except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
Nitisinone
Nomegestrol
Nystatin; except when specified elsewhere in this notice; except in medicines for tinea pedis only or when sold in practice by a podiatrist registered with the Podiatrists Board
Ofatumumab
Omeprazole; except when specified elsewhere in this notice
Pantoprazole; except when specified elsewhere in this notice
Plerixafor
Prucalopride
Pseudoephedrine
Remestemcel-L
Rilpivirine
Rupatadine
Sapropterin
Tafluprost
Telaprevir
Terbinafine; except in medicines for dermal use
Ticagrelor
Tioconazole; except in medicines for vaginal or dermal use
Tolvaptan
Tuberculin
Vemurafenib
Vorinostat

Schedule 2

Restricted Medicines

Brompheniramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of anxiety or insomnia; for oral use for the treatment of anxiety or insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units

Chlorpheniramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of anxiety or insomnia; for oral use for the treatment of anxiety or insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units

Cimetidine; in medicines for the symptomatic relief of heartburn, dyspepsia and hyperacidity or to be used on the recommendation of a registered medical practitioner that are sold in the manufacturer’s original pack containing not more than 14 days’ supply

Cyclizine; for oral use other than in medicines used for the treatment of anxiety or insomnia; for oral use for the treatment of anxiety or insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units

Dexchlorpheniramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of anxiety or insomnia; for oral use for the treatment of anxiety or insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units

Diclofenac; in solid dose form in medicines containing 25 milligrams or less and more than 12.5 milligrams per dose form in packs containing not more than 30 tablets or capsules

Diphenhydramine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of anxiety or insomnia; for oral use for the treatment of anxiety or insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units

Doxylamine; for oral use in medicines for adults or children over 2 years of age other than in medicines used for the treatment of anxiety or insomnia; for oral use for the treatment of anxiety or insomnia when sold in the manufacturer’s original pack containing not more than 10 dosage units

Famciclovir; in divided solid dosage forms for oral use containing 500 milligrams or less for the treatment of recurrent herpes labialis when sold in the manufacturer’s original pack containing up to 3 dosage units

Guaiphenesin; for oral use in modified release form with a maximum recommended daily dose of not more than 2.4 grams when sold in the manufacturer’s original pack



Next Page →



Online Sources for this page:

Gazette.govt.nz PDF NZ Gazette 2012, No 11





✨ LLM interpretation of page content

🏥 Classification of Medicines under the Medicines Act 1981 (continued from previous page)

🏥 Health & Social Welfare
Medicines, Classification, Prescription, Restricted, Pharmacy-only